Orals

SLU-PP-332 20mg

Name: SLU-PP-332 20mg
Brand: Quanta Pharmaceuticals

ERRα/γ agonist researched as an exercise-mimetic for endurance, mitochondrial function and fat oxidation.

SLU-PP-332 is a synthetic ERRα/γ (estrogen-related receptor alpha and gamma) agonist that has become one of the most closely watched compounds in exercise-mimetic research. Often described as "exercise in a pill," it is studied for its ability to reproduce many of the metabolic adaptations associated with endurance training, without requiring physical activity in preclinical models. Each tablet is supplied at a labelled 20mg dose. Independent third-party lab testing of this batch confirmed an actual content of 21.87mg per tablet, indicating a slight overage against label claim rather than any shortfall. Research interest in SLU-PP-332 centres on its role as a metabolic and mitochondrial regulator, positioning it as a next-generation subject of study alongside older PPAR-targeted endurance compounds in the literature.

Verify a product

Specifications

Tablets

Dose Per Tablet

20mg

Verified Content

21.87mg per tablet (independent third-party lab testing)

Half-Life

4-6 hours

Administration

Oral

Research Benefits

Enhanced Endurance — Preclinical research reports meaningful improvements in exercise capacity and running stamina.
Metabolic Activation — Studied for its activation of ERR receptors that govern energy metabolism and mitochondrial biogenesis.
Fat Oxidation — Research points to an increased capacity to utilise fat as a primary fuel source during activity.
Muscle Fibre Adaptation — Studies describe a shift toward oxidative, slow-twitch muscle fibre characteristics.
Training-Independent Effects — Notably, research models show these adaptations occurring even without an exercise stimulus.
Verified Dosing — Independent lab testing confirms accurate, consistent tablet content batch to batch.

How It Works

SLU-PP-332 works by directly activating estrogen-related receptors alpha and gamma (ERRα/γ), nuclear receptors that sit at the centre of cellular energy metabolism, mitochondrial biogenesis, and oxidative phosphorylation. Activating these receptors switches on gene programmes responsible for fatty acid oxidation, glucose handling, and the production of new mitochondria.

In published preclinical research, this receptor activation has been shown to mimic many of the physiological adaptations normally driven by sustained endurance exercise. Animal studies have reported marked improvements in running endurance, a shift toward oxidative muscle fibre type, and favourable changes in metabolic markers — all without an accompanying training stimulus.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. SLU-PP-332 20mg must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.